STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug

Patient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences. The item does not provide specific safety data or conclusions.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.